REGENXBIO Announces Proposed $125M Public Offering Of Common Stock
Portfolio Pulse from Benzinga Newsdesk
REGENXBIO Inc. (NASDAQ:RGNX) announced its plan to offer $125M of its common stock in an underwritten public offering, subject to market conditions. The offering's completion, size, or terms are not guaranteed. REGENXBIO will also give underwriters a 30-day option to buy up to 15% more shares. Morgan Stanley, Goldman Sachs & Co. LLC, Barclays, and Stifel are the joint book-running managers.
March 06, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
REGENXBIO Inc. is planning a $125M public offering of its common stock, with potential additional sales to underwriters, managed by major financial institutions.
Public offerings often lead to short-term price declines due to the dilution of existing shares. The announcement of a significant offering like this can create uncertainty about the stock's value, potentially leading to a decrease in its price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100